TRANSFAC FACTOR TABLE, Release 2017.2 - public - 2017-06-30, (C) QIAGEN

AC T01806 XX ID T01806 XX DT 13.05.1996 (created); dbo. DT 14.04.2015 (updated); asv. CO Copyright (C), QIAGEN. XX FA p53 XX SY ASp53; cellular tumor antigen p53; NSp53; p53; p53as; RSp53; TP53; TRP53. XX OS mouse, Mus musculus OC eukaryota; animalia; metazoa; chordata; vertebrata; tetrapoda; mammalia; eutheria; rodentia; myomorpha; muridae; murinae XX GE G000583 Trp53. XX CL C0057; P53; XX SF alternative splice variant mRNA: p53as [9] [20] [46]; SF several proteins may be synthesized from each p53 mRNA species [20]; SF unspecific DNA-binding of the C-terminal part of the molecule [17]; SF C-terminal part: tetramerization and minimal transformation domain [19]; SF interaction with short DNA-fragments can relieve inhibition by the C-terminal part and stimulates sequence-specific DNA binding of p53 [10]; SF free in solution, tetramers form and adopt an extended shape [28] [49]; SF DNA-binding as tetramers [49]; SF also able to bind and transactivate as monomers and dimers (e. g. in truncated variants) [8]; SF highly cooperative binding of four monomers (lacking the tetramerization domain) to DNA if the binding sites are in a favorable stereoalignment [11]; SF tetramers bound to distant sites are able to stack thus causing looping of DNA and enhanced trans-activation [47]; SF tetramerization domain coincides with that responsible for cellular transformation by certain oncogenes [48]; SF p53 has been found covalently linked to 5.8S rRNA and in a complex with Mdm-2, ribosomal protein L5 and 5S rRNA [35] [44]; SF also interacts with the proteins 53BP1 and 53BP2 [45]; XX EX mouse, Mus musculus,,,embryo; detectable; immunohistochemistry / immunocytochemistry; protein; [61]. XX FF transcription factor, look up the TRANSFAC cross reference for more details; FF activator [12] [24] [25]; FF tumor suppressor [15] [21] [22] [23]; FF sequence-specific DNA-binding protein [25]; FF homozygous null allele mice develop normally but spontaneously develop tumors [36]; FF due to enhanced malignant progression rather than to increased initiation [37]; FF negative regulation of c-myc [29]; FF positive autoregulation, probably through an indirect mechanism [3]; FF peak of expression in the G1 phase [46]; FF several viral regulators shut off cell cycle control by p53 [13] [24]; FF inhibitory interactions have been shown with Mdm-2 [7] [32] [33]; FF mdm2 gene is activated by p53 [6] [38]; FF phosphorylation by casein kinase II (CK II) [18]; FF phosphorylation at Ser-389 in SV40-transformed cells depends upon large T antigen and may be involved in cell transformation [54]; FF Ser-389 may also be linked to RNA; FF phosphate at Ser-312 appears to be in a phosphodiester bond [54]; FF at least certain mutated forms containing mutations in the central core domain are active in S/MAR binding [55] [56]; FF mutant (MethA) interacts specifically with S/MARs in regions with high potential for base-unpairing, binding depends on structural instability [57]; FF mutant (MethA) proposed to promote local base-unpairing in unwinding S/MAR regions [57]; XX IN T05109 53BP1; human, Homo sapiens. IN T01318 CBP; mouse, Mus musculus. IN T01549 DP-1; mouse, Mus musculus. IN T00305 GATA-1; mouse, Mus musculus. IN T18835 Mi2-alpha; human, Homo sapiens. IN T10542 p300; mouse, Mus musculus. IN T01806 p53; mouse, Mus musculus. IN T02103 p53as; mouse, Mus musculus. IN T32110 SIRT1; mouse, Mus musculus. IN T08951 STAT1; mouse, Mus musculus. IN T00788 T-Ag; SV40, simian virus 40. IN T00796 TBP; mouse, Mus musculus. IN T02351 WT1; mouse, Mus musculus. IN T04355 zhx1; human, Homo sapiens. XX MX M00761 V$P53DECAMER_Q2. MX M00034 V$P53_01. MX M00272 V$P53_02. MX M01651 V$P53_03. MX M01652 V$P53_04. MX M01655 V$P53_05. MX M07054 V$P53_Q3_01. XX BS R12753. BS R22089. BS R11272. BS R29992. BS R16322. BS R11694. BS R11387. BS R36503. BS R11385. BS R11386. BS R28000. BS R31575. BS R62550. BS R15778. BS R15779. BS R26896. BS R26894. BS R04377. BS R15777. BS R72779. BS R31925. BS R31926. BS R71299. BS R71316. BS R11384. BS R25464. BS R25465. BS R67170. BS R67173. BS R57733. BS R11442. BS R11437. BS R16704. BS R61722. BS R61723. BS R61724. BS R59814. BS R20521. BS R71313. BS R71315. BS R30952. BS R63171. BS R32562. BS R32563. BS R38913. XX DR TRANSPATH: MO000010547. DR TRANSCOMPEL: C00289. DR SMARTDB: SB000029. DR UniProtKB: P02340; XX RN [1]; RE0001171. RX PUBMED: 1851875. RA Loeber G., Stenger J. E., Ray S., Parsons R. E., Anderson M. E., Tegtmeyer P. RT The zinc finger region of simian virus 40 large T antigen is needed for hexamer assembly and origin melting RL J. Virol. 65:3167-3174 (1991). RN [2]; RE0004158. RX PUBMED: 7957050. RA Okamoto K., Beach D. RT Cyclin G is a transcriptional Target of the p53 tumor suppressor protein RL EMBO J. 13:4816-4822 (1994). RN [3]; RE0004313. RX PUBMED: 7684498. RA Deffie A., Wu H., Reinke V., Lozano G. RT The tumor suppressor p53 regulates its own transcription RL Mol. Cell. Biol. 13:3415-3423 (1993). RN [4]; RE0004315. RX PUBMED: 6092064. RA Bienz B., Zakut-Houri R., Givol D., Oren M. RT Analysis of the gene coding for the murine cellular tumor antigen p53 RL EMBO J. 3:2179-2183 (1984). RN [5]; RE0005388. RX PUBMED: 8265599. RA Perry M. E., Piette J., Zawakzki J. A., Harvey D., Levine A. J. RT The mdm-2 gene is induced in response to UV light in a p53-dependent manner RL Proc. Natl. Acad. Sci. USA 90:11623-11627 (1993). RN [6]; RE0005390. RX PUBMED: 8319905. RA Wu X., Bayle J. H., Olson D., Levine A. J. RT The p53-mdm-2 autoregulatory feedback loop RL Genes Dev. 7:1126-1132 (1993). RN [7]; RE0005392. RX PUBMED: 8334996. RA Zauberman A., Barak Y., Ragimov N., Levy N., Oren M. RT Sequence-specific DNA binding by p53: identifikation of target sites and lack of binding to p53-MDM2 complexes RL EMBO J. 12:2799-2808 (1993). RN [8]; RE0005393. RX PUBMED: 8334995. RA Shaulian E., Zauberman A., Milner J., Davies E. A., Oren M. RT Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation RL EMBO J. 12:2789-2797 (1993). RN [9]; RE0005400. RX PUBMED: 7624329. RA Wolkowicz R., Peled A., Elkind N. B., Rotter V. RT Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form RL Proc. Natl. Acad. Sci. USA 92:6842-6846 (1995). RN [10]; RE0005404. RX PUBMED: 7600571. RA Jayaraman L., Prives C. RT Activation of p53 Sequence-Specific DNA Binding by Short Single Strands of DNA Requires the p53 C-Terminus RL Cell 81:1021-1029 (1995). RN [11]; RE0005405. RX PUBMED: 7891710. RA Wang Y., Schwedes J. F., Parks D., Mann K., Tegtmeyer P. RT Interaction of p53 with its consensus DNA-binding site RL Mol. Cell. Biol. 15:2157-2165 (1995). RN [12]; RE0005411. RX PUBMED: 2144364. RA Raycroft L., Wu H., Lozano G. RT Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene RL Science 249:1049-1051 (1990). RN [13]; RE0005412. RX PUBMED: 1649323. RA Michael-Michalovitz D., Yhiely F., Gottlieb E., Oren M. RT Simian virus 40 can overcome the antiproliferative effect of wild-type p53 in the absence of stable large T antigen-p53 binding RL J. Virol. 65:4160-4168 (1991). RN [14]; RE0005416. RX PUBMED: 222475. RA Linzer D. I. H., Levine A. J. RT Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells RL Cell 17:43-52 (1979). RN [15]; RE0005418. RX PUBMED: 2046748. RA Levine A. J., Momand J., Finlay C. A. RT The p53 tumour suppressor gene RL Nature 351:453-457 (1991). RN [16]; RE0005419. RX PUBMED: 1646078. RA Bargonetti J., Friedman P. N., Kern S. E., Vogelstein B., Prives C. RT Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication RL Cell 65:1083-1091 (1991). RN [17]; RE0005420. RX PUBMED: 1923804. RA Foord O. S., Bhattacharya P., Reich Z., Rotter V. RT A DNA binding domain is contained in the C-terminus of wild-type p53 protein RL Nucleic Acids Res. 19:5191-5198 (1991). RN [18]; RE0005422. RX PUBMED: 1400378. RA Filhol O., Baudier J., Delphin C., Loue-Mackenbach P., Chambaz E. M., Cochet C. RT Casein kinase II and the tumor suppressor protein P53 associate in a molecular complex that is negatively regulated upon P53 phosphorylation RL J. Biol. Chem. 267:20577-20583 (1992). RN [19]; RE0005423. RX PUBMED: 1448088. RA Shaulian E., Zauberman A., Ginsberg D., Oren M. RT Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding RL Mol. Cell. Biol. 12:5581-5592 (1992). RN [20]; RE0005424. RX PUBMED: 1579500. RA Han K.-A., Kulesz-Martin M. F. RT Alternatively splice p53 RNA in transformed and normal cells of different tissue types RL Nucleic Acids Res. 20:1979-1981 (1992). RN [21]; RE0005425. RX PUBMED: 2525423. RA Finlay C. A., Hinds P. W., Levine A. J. RT The p53 proto-oncogene can act as a supressor of transformation RL Cell 57:1083-1093 (1989). RN [22]; RE0005426. RX PUBMED: 2530586. RA Eliyahu D., Michalovitz D., Eliyahu S., Pinhasi-Kimhi O., Oren M. RT Wild-type p53 can inhibit oncogene-mediated focus formation RL Proc. Natl. Acad. Sci. USA 86:8763-8767 (1989). RN [23]; RE0005427. RX PUBMED: 1659741. RA Weinberg R. A. RT Tumor suppressor genes RL Science 254:1138-1146 (1991). RN [24]; RE0005428. RX PUBMED: 1614538. RA Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., Prives C. RT Wild-type p53 activates transcription in vitro RL Nature 358:83-86 (1992). RN [25]; RE0005429. RX PUBMED: 1628822. RA Zambetti G. P., Bargonetti J., Walker K., Prives C., Levine A. J. RT Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element RL Genes Dev. 6:1143-1152 (1992). RN [26]; RE0005430. RX PUBMED: 2827007. RA Meek D. W., Eckhart W. RT Phosphorylation of p53 in normal and simian virus 40-transformed NIH 3T3 cells RL Mol. Cell. Biol. 8:461-465 (1988). RN [27]; RE0005431. RX PUBMED: 2145148. RA Meek D. W., Simon S., Kikkawa U., Eckhart W. RT The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II RL EMBO J. 9:3253-3260 (1990). RN [28]; RE0005435. RX PUBMED: 1554407. RA Stenger J. E., Mayr G. A., Mann K., Tegtmeyer P. RT Formation of stable p53 homotetramers and multiples of tetramers RL Mol. Carcinog. 5:102-106 (1992). RN [29]; RE0005440. RX PUBMED: 1400626. RA Moberg K. H., Tyndall W. A., Hall D. J. RT Wild-type murine p53 represses transcription from the murine c-myc promoter in a human glial cell line RL J. Cell. Biochem. 49:208-215 (1992). RN [30]; RE0005441. RX PUBMED: 1584757. RA Wang Y., Eckhart W. RT Phosphorylation sites in the amino-terminal region of mouse p53 RL Proc. Natl. Acad. Sci. USA 89:4231-4235 (1992). RN [31]; RE0005443. RX PUBMED: 3006031. RA Samad A., Anderson C. W., Carroll R. B. RT Mapping of phosphomonoester and apparent phosphodiester bonds of the oncogene product p53 from simian virus 40-transformed 3T3 cells RL Proc. Natl. Acad. Sci. USA 83:897-901 (1986). RN [32]; RE0005447. RX PUBMED: 1600943. RA Barak Y., Oren M. RT Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest RL EMBO J. 11:2115-2121 (1992). RN [33]; RE0005448. RX PUBMED: 1535557. RA Momand J., Zambetti G. P., Olson D. C., Levine D., George A. J. RT the mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivatioN RL Cell 69:1237-1245 (1992). RN [34]; RE0005449. RX PUBMED: 1406679. RA Lees-Miller S. P., Sakaguchi K., Ullrich S. J., Appella E., Anderson C. W. RT Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. RL Mol. Cell. Biol. 12:5041-5049 (1992). RN [35]; RE0005450. RX PUBMED: 1406686. RA Fontoura B. M., Sorokina E. A., David E., Carroll R. B. RT p53 is covalently linked to 5.8S rRNA RL Mol. Cell. Biol. 12:5145-5151 (1992). RN [36]; RE0005451. RX PUBMED: 1552940. RA Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery jr C. A., Butel J. S., Bradley A. RT Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours RL Nature 356:215-221 (1992). RN [37]; RE0005455. RX PUBMED: 8374952. RA Kemp C. J., Donehower L. A., Bradley A., Balmain A. RT Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors RL Cell 74:813-822 (1993). RN [38]; RE0005459. RX PUBMED: 8440237. RA Barak Y., Juven T., Haffner R., Oren M. RT mdm2 expression is induced by wild type p53 activity RL EMBO J. 12:461-468 (1993). RN [39]; RE0005460. RX PUBMED: 8384579. RA Lowe S. W., Ruley H. E. RT Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis RL Genes Dev. 7:535-545 (1993). RN [40]; RE0005461. RX PUBMED: 8384580. RA Debbas M., White E. RT Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B RL Genes Dev. 7:546-554 (1993). RN [41]; RE0005464. RX PUBMED: 8276240. RA Wang Y., Reed M., Wang P., Stenger J. E., Mayr G., Anderson M. E., Schwedes J. F., Tegtmeyer P. RT p53 domains: identification and characterization of two autonomous DNA-binding regions RL Genes Dev. 7:2575-2586 (1993). RN [42]; RE0005466. RX PUBMED: 8387645. RA Mack D. H., Vartikar J., Pipas J. M., Laimins L. A. RT Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 RL Nature 363:281-283 (1993). RN [43]; RE0005467. RX PUBMED: 7969181. RA Zhao J., Schmieg F. I., Simmons D. T., Molloy G. R. RT Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene RL Mol. Cell. Biol. 14:8483-8492 (1994). RN [44]; RE0005468. RX PUBMED: 7935455. RA Marechal V., Elenbaas B., Piette J., Nicolas J.-C., Levine A. J. RT The ribosomal L5 protein is associated with mdm-2 and mdmd-2-p53 complexes RL Mol. Cell. Biol. 14:7414-7420 (1994). RN [45]; RE0005469. RX PUBMED: 8016121. RA Iwabuchi K., Bartel P. L., Lin B., Marraccino R., Fields S. RT Two cellular proteins that bind to wild-type but not mutant p53 RL Proc. Natl. Acad. Sci. USA 91:6098-6102 (1994). RN [46]; RE0005471. RX PUBMED: 8114705. RA Kulesz-Martin M. F., Lisafeld B., Huang H., Kisiel N. D., Lee L. RT Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells RL Mol. Cell. Biol. 14:1698-1708 (1994). RN [47]; RE0005472. RX PUBMED: 7813439. RA Stenger J. E., Tegtmeyer P., Mayr G., Reed M., Wang Y., Wang P., Hough P. V. C., Mastrangelo I. A. RT p53 oligomerization and DNA looping are linked with transcriptional activation RL EMBO J. 13:6011-6020 (1994). RN [48]; RE0005477. RX PUBMED: 8035799. RA Wang P., Reed M., Wang W., Mayr G., Stenger J. E., Anderson M. E., Schwedes J. F., Tegtmeyer P. RT p53 domains: Structure, oligomerization, and transformation RL Mol. Cell. Biol. 14:5182-5191 (1994). RN [49]; RE0005478. RX PUBMED: 7957051. RA Wu Y., Liu Y., Lee L., Miner Z., Kulesz-Martin M. RT Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells RL EMBO J. 13:4823-4830 (1994). RN [50]; RE0005479. RX PUBMED: 7777576. RA Bayle J. H., Elenbaas B., Levine A. J. RT The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity RL Proc. Natl. Acad. Sci. USA 92:5729-5733 (1995). RN [51]; RE0005490. RX PUBMED: 6646235. RA Zakut-Houri R., Oren M., Bienz B., Lavie V., Hazum S., Givol D. RT A single gene and a pseudogene for the cellular tumour antigen p53 RL Nature 306:5609-5626 (1983). RN [52]; RE0005491. RX PUBMED: 6379601. RA Jenkins J. R., Rudge K., Redmond S., Wade-Evans A. RT Cloning and expression analysis of full length mouse cDNA sequences encoding the transformation associated protein p53 RL Nucleic Acids Res. 12:5609-5626 (1984). RN [53]; RE0005492. RX PUBMED: 3023970. RA Arai N., Nomura D., Yokota K., Wolf D., Brill E., Shohat O., Rotter V. RT Immunologically distinct p53 molecules generated by alternative splicing RL Mol. Cell. Biol. 6:3232-3239 (1986). RN [54]; RE0005494. RA Anderson C. W., Samad A., Carroll R. B. RT Identification and characterization of the site phosphorylated in the cellular tumor antigen p53 from SV40-transformed 3T3 cells and in the DNA-binding protein from adenovirus 2 RL Cancer Cells 4:395-404 (1986). RN [55]; RE0007121. RX PUBMED: 8844397. RA Deppert W. RT Binding of Mar-DNA elements by mutant p53: possible implications for its oncogenic functions RL J. Cell. Biochem. 62:172-180 (1996). RN [56]; RE0007141. RX PUBMED: 9581865. RA Will K., Warnecke G., Albrechtsen N., Boulikas T., Deppert W. RT High affinity MAR-DNA binding is a common property of murine and human mutant p53 RL J. Cell. Biochem. 69:260-270 (1998). RN [57]; RE0013401. RX PUBMED: 9811860. RA Will K., Warnecke G., Wiesmueller L., Deppert W. RT Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing RL Proc. Natl. Acad. Sci. USA 95:13681-13686 (1998). RN [58]; RE0017022. RX PUBMED: 10594026. RA Gu Z., Flemington C., Chittenden T., Zambetti G. P. RT ei24, a p53 response gene involved in growth suppression and apoptosis. RL Mol. Cell. Biol. 20:233-241 (2000). RN [59]; RE0019322. RX PUBMED: 1766680. RA BURNS P.A., KEMP C.J., GANNON J.V., LANE D.P., BREMNER R., BALMAIN A. RT Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. RL Oncogene 6:2363-2369 (1991). RN [60]; RE0020825. RX PUBMED: 11672522. RA Luo J., Nikolaev A. Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. RT Negative control of p53 by Sir2alpha promotes cell survival under stress RL Cell 107:137-148 (2001). RN [61]; RE0021120. RX PUBMED: 10559859. RA Weber J. D., Taylor L. J., Roussel M. F., Sherr C. J., Bar-Sagi D. RT Nucleolar Arf sequesters Mdm2 and activates p53 RL Nat. Cell Biol. 1:20-26 (1999). RN [62]; RE0021154. RX PUBMED: 11495913. RA Kishi H., Nakagawa K., Matsumoto M., Suga M., Ando M., Taya Y., Yamaizumi M. RT Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20 RL J. Biol. Chem. 276:39115-39122 (2001). RN [63]; RE0024555. RX PUBMED: 14985507. RA Fiucci G., Beaucourt S., Duflaut D., Lespagnol A., Stumptner-Cuvelette P., Geant A., Buchwalter G., Tuynder M., Susini L., Lassalle J. M., Wasylyk C., Wasylyk B., Oren M., Amson R., Telerman A. RT Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. RL Proc. Natl. Acad. Sci. USA 101:3510-3515 (2004). RN [64]; RE0040557. RX PUBMED: 10871855. RA Brown A., Browes C., Mitchell M., Montano X. RT c-abl is involved in the association of p53 and trk A RL Oncogene 19:3032-40 (2000). RN [65]; RE0042645. RX PUBMED: 12791272. RA Zenz R., Scheuch H., Martin P., Frank C., Eferl R., Kenner L., Sibilia M., Wagner E. F. RT c-Jun regulates eyelid closure and skin tumor development through EGFR signaling RL Dev. Cell 4:879-89 (2003). RN [66]; RE0047378. RX PUBMED: 11359766. RA Zhang T., Prives C. RT Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. RL J. Biol. Chem. 276:29702-29710 (2001). RN [67]; RE0047581. RX PUBMED: 16055726. RA Kulikov R., Boehme K. A., Blattner C. RT Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. RL Mol. Cell. Biol. 25:7170-7180 (2005). RN [68]; RE0047711. RX PUBMED: 12426395. RA Ito A., Kawaguchi Y., Lai C. H., Kovacs J. J., Higashimoto Y., Appella E., Yao T. P. RT MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. RL EMBO J. 21:6236-6245 (2002). RN [69]; RE0047946. RX PUBMED: 15563594. RA Wang R. H., Yu H., Deng C. X. RT A requirement for breast-cancer-associated gene 1 (BRCA1) in the spindle checkpoint. RL Proc. Natl. Acad. Sci. USA 101:17108-17113 (2004). RN [70]; RE0048055. RX PUBMED: 15383276. RA Goehler H., Lalowski M., Stelzl U., Waelter S., Stroedicke M., Worm U., Droege A., Lindenberg K. S., Knoblich M., Haenig C., Herbst M., Suopanki J., Scherzinger E., Abraham C., Bauer B., Hasenbank R., Fritzsche A., Ludewig A. H., Bussow K., Coleman S. H., Gutekunst C. A., Landwehrmeyer B. G., Lehrach H., Wanker E. E. RT A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. RL Mol. Cell 15:853-865 (2004). RN [71]; RE0048328. RX PUBMED: 16254014. RA Khan O. Y., Fu G., Ismail A., Srinivasan S., Cao X., Tu Y., Lu S., Nawaz Z. RT Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. RL Mol. Endocrinol. 20:544-559 (2006). RN [72]; RE0048854. RX PUBMED: 15989966. RA Yuan X., Zhou Y., Casanova E., Chai M., Kiss E., Grone H. J., Schutz G., Grummt I. RT Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. RL Mol. Cell 19:77-87 (2005). RN [73]; RE0048959. RX PUBMED: 16949371. RA Shreeram S., Demidov O. N., Hee W. K., Yamaguchi H., Onishi N., Kek C., Timofeev O. N., Dudgeon C., Fornace A. J., Anderson C. W., Minami Y., Appella E., Bulavin D. V. RT Wip1 phosphatase modulates ATM-dependent signaling pathways. RL Mol. Cell 23:757-764 (2006). RN [74]; RE0049040. RX PUBMED: 15983031. RA Seth R., Yang C., Kaushal V., Shah S. V., Kaushal G. P. RT p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. RL J. Biol. Chem. 280:31230-31239 (2005). RN [75]; RE0049133. RX PUBMED: 17110379. RA Tompkins V. S., Hagen J., Frazier A. A., Lushnikova T., Fitzgerald M. P., Tommaso A. D., Ladeveze V., Domann F. E., Eischen C. M., Quelle D. E. RT A novel nuclear interactor of ARF and Mdm2 (NIAM) that maintains chromosomal stability. RL J. Biol. Chem. 282:1322-1333 (2006). RN [76]; RE0049287. RX PUBMED: 16607280. RA Gonzalez L., Freije J. M., Cal S., Lopez-Otin C., Serrano M., Palmero I. RT A functional link between the tumour suppressors ARF and p33ING1. RL Oncogene 25:5173 (2006). RN [77]; RE0049505. RX PUBMED: 14602726. RA Townsend P. A., Scarabelli T. M., Davidson S. M., Knight R. A., Latchman D. S., Stephanou A. RT STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. RL J. Biol. Chem. 279:5811-5820 (2004). RN [78]; RE0049976. RX PUBMED: 17434128. RA Huang W. C., Ju T. K., Hung M. C., Chen C. C. RT Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. RL Mol. Cell 26:75-87 (2007). RN [79]; RE0050504. RX PUBMED: 16845383. RA Tang J., Qu L. K., Zhang J., Wang W., Michaelson J. S., Degenhardt Y. Y., El-Deiry W. S., Yang X. RT Critical role for Daxx in regulating Mdm2. RL Nat. Cell Biol. 8:855-862 (2006). RN [80]; RE0050624. RX PUBMED: 16763046. RA Alves da Costa C., Sunyach C., Pardossi-Piquard R., Sevalle J., Vincent B., Boyer N., Kawarai T., Girardot N., St George-Hyslop P., Checler F. RT Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. RL J. Neurosci. 26:6377-6385 (2006). RN [81]; RE0053139. RX PUBMED: 16571599. RA Yamada T., Ishihara H., Tamura A., Takahashi R., Yamaguchi S., Takei D., Tokita A., Satake C., Tashiro F., Katagiri H., Aburatani H., Miyazaki J., Oka Y. RT WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic pathway specifically in pancreatic beta-cells. RL Hum. Mol. Genet. 15:1600-1609 (2006). RN [82]; RE0053140. RX PUBMED: 12154087. RA Hasan M. K., Yaguchi T., Sugihara T., Kumar P. K., Taira K., Reddel R. R., Kaul S. C., Wadhwa R. RT CARF is a novel protein that cooperates with mouse p19ARF (human p14ARF) in activating p53. RL J. Biol. Chem. 277:37765-37770 (2002). RN [83]; RE0053560. RX PUBMED: 18471976. RA Basak S., Jacobs S. B., Krieg A. J., Pathak N., Zeng Q., Kaldis P., Giaccia A. J., Attardi L. D. RT The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. RL Mol. Cell 30:303-314 (2008). RN [84]; RE0055193. RX PUBMED: 16166097. RA Lebrun P., Montminy M. R., Van Obberghen E. RT Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase. RL J. Biol. Chem. 280:38203-38210 (2005). RN [85]; RE0062898. RX PUBMED: 16418486. RA Boiko A. D., Porteous S., Razorenova O. V., Krivokrysenko V. I., Williams B. R., Gudkov A. V. RT A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. RL Genes Dev. 20:236-252 (2006). RN [86]; RE0063261. RX PUBMED: 16169070. RA Stelzl U., Worm U., Lalowski M., Haenig C., Brembeck F. H., Goehler H., Stroedicke M., Zenkner M., Schoenherr A., Koeppen S., Timm J., Mintzlaff S., Abraham C., Bock N., Kietzmann S., Goedde A., Toksoz E., Droege A., Krobitsch S., Korn B., Birchmeier W., Lehrach H., Wanker E. E. RT A human protein-protein interaction network: a resource for annotating the proteome. RL Cell 122:957-968 (2005). RN [87]; RE0064377. RX PUBMED: 17999388. RA Golubovskaya V. M., Finch R., Kweh F., Massoll N. A., Campbell-Thompson M., Wallace M. R., Cance W. G. RT p53 regulates FAK expression in human tumor cells. RL Mol. Carcinog. 47:373-382 (2008). RN [88]; RE0064484. RX PUBMED: 17693405. RA Wang J., Liu Y. X., Hande M. P., Wong A. C., Jin Y. J., Yin Y. RT TAp73 is a downstream target of p53 in controlling the cellular defense against stress. RL J. Biol. Chem. 282:29152-29162 (2007). RN [89]; RE0064535. RX PUBMED: 19088189. RA Mandal M., Crusio K. M., Meng F., Liu S., Kinsella M., Clark M. R., Takeuchi O., Aifantis I. RT Regulation of lymphocyte progenitor survival by the proapoptotic activities of Bim and Bid. RL Proc. Natl. Acad. Sci. USA 105:20840-20845 (2008). RN [90]; RE0065063. RX PUBMED: 19357269. RA Lau D., Bading H. RT Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. RL J. Neurosci. 29:4420-4429 (2009). RN [91]; RE0065166. RX PUBMED: 19448627. RA Wang S. P., Wang W. L., Chang Y. L., Wu C. T., Chao Y. C., Kao S. H., Yuan A., Lin C. W., Yang S. C., Chan W. K., Li K. C., Hong T. M., Yang P. C. RT p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. RL Nat. Cell Biol. 11:694-704 (2009). RN [92]; RE0065251. RX PUBMED: 18566590. RA Song M. S., Song S. J., Kim S. Y., Oh H. J., Lim D. S. RT The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. RL EMBO J. 27:1863-1874 (2008). RN [93]; RE0065335. RX PUBMED: 19079244. RA Kim Y. C., Gerlitz G., Furusawa T., Catez F., Nussenzweig A., Oh K. S., Kraemer K. H., Shiloh Y., Bustin M. RT Activation of ATM depends on chromatin interactions occurring before induction of DNA damage. RL Nat. Cell Biol. 11:92-96 (2009). RN [94]; RE0065678. RX PUBMED: 19287375. RA Fumagalli S., Di Cara A., Neb-Gulati A., Natt F., Schwemberger S., Hall J., Babcock G. F., Bernardi R., Pandolfi P. P., Thomas G. RT Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. RL Nat. Cell Biol. 11:501-508 (2009). RN [95]; RE0065683. RX PUBMED: 20016601. RA Chen D., Pacal M., Wenzel P., Knoepfler P. S., Leone G., Bremner R. RT Division and apoptosis of E2f-deficient retinal progenitors. RL Nature 462:925-929 (2009). RN [96]; RE0066278. RX PUBMED: 19098008. RA Murase D., Hachiya A., Amano Y., Ohuchi A., Kitahara T., Takema Y. RT The essential role of p53 in hyperpigmentation of the skin via regulation of paracrine melanogenic cytokine receptor signaling. RL J. Biol. Chem. 284:4343-4353 (2009). RN [97]; RE0066671. RX PUBMED: 19026785. RA Yang G., Li Y., Nishimura E. K., Xin H., Zhou A., Guo Y., Dong L., Denning M. F., Nickoloff B. J., Cui R. RT Inhibition of PAX3 by TGF-beta modulates melanocyte viability. RL Mol. Cell 32:554-563 (2008). RN [98]; RE0066736. RX PUBMED: 12872134. RA Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., Sasaki S., Imai K., Shibue T., Honda K., Taniguchi T. RT Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. RL Nature 424:516-523 (2003). RN [99]; RE0066926. RX PUBMED: 19049493. RA Cuesta A., Zambrano A., Royo M., Pascual A. RT The tumour suppressor p53 regulates the expression of amyloid precursor protein (APP). RL Biochem. J. 418:643-650 (2009). RN [100]; RE0066981. RX PUBMED: 17350573. RA Cui R., Widlund H. R., Feige E., Lin J. Y., Wilensky D. L., Igras V. E., D Orazio J., Fung C. Y., Schanbacher C. F., Granter S. R., Fisher D. E. RT Central role of p53 in the suntan response and pathologic hyperpigmentation. RL Cell 128:853-864 (2007). RN [101]; RE0068818. RX PUBMED: 17936559. RT The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. RL Cancer Cell 12:342-354 (2007). RN [102]; RE0069042. RX PUBMED: 20351271. RA Suzuki S., Tanaka T., Poyurovsky M. V., Nagano H., Mayama T., Ohkubo S., Lokshin M., Hosokawa H., Nakayama T., Suzuki Y., Sugano S., Sato E., Nagao T., Yokote K., Tatsuno I., Prives C. RT Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. RL Proc. Natl. Acad. Sci. USA 107:7461-7466 (2010). RN [103]; RE0069068. RX PUBMED: 19766563. RA Cicalese A., Bonizzi G., Pasi C. E., Faretta M., Ronzoni S., Giulini B., Brisken C., Minucci S., Di Fiore P. P., Pelicci P. G. RT The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. RL Cell 138:1083-1095 (2009). RN [104]; RE0069555. RX PUBMED: 20962274. RA Slee E. A., Benassi B., Goldin R., Zhong S., Ratnayaka I., Blandino G., Lu X. RT Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. RL Proc. Natl. Acad. Sci. USA 107:19479-19484 (2010). RN [105]; RE0071030. RX PUBMED: 18996350. RA Habib G. M. RT p53 regulates Hsp90beta during arsenite-induced cytotoxicity in glutathione-deficient cells. RL Arch. Biochem. Biophys. 481:101-109 (2009). RN [106]; RE0024373. RX PUBMED: 12397362. RA Zacchi P., Gostissa M., Uchida T., Salvagno C., Avolio F., Volinia S., Ronai Z., Blandino G., Schneider C., Del Sal G. RT The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. RL Nature 419:853-857 (2002). XX //